Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

Akebia Therapeutics (AKBA) Accumulated Depreciation & Amortization: 2016-2022

Historic Accumulated Depreciation & Amortization for Akebia Therapeutics (AKBA) over the last 5 years, with Dec 2022 value amounting to $9.3 million.

  • Akebia Therapeutics' Accumulated Depreciation & Amortization rose 21.58% to $9.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was $27.9 million, marking a year-over-year increase of 19.75%. This contributed to the annual value of $1.7 million for FY2022, which is 14.17% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Accumulated Depreciation & Amortization of $9.3 million as of Q4 2022, which was up 21.58% from $7.7 million recorded in Q4 2021.
  • In the past 5 years, Akebia Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $9.3 million in Q4 2022 and a low of $1.3 million during Q1 2018.
  • Its 3-year average for Accumulated Depreciation & Amortization is $6.1 million, with a median of $5.5 million in 2020.
  • Data for Akebia Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY soared of 117.65% (in 2018) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $2.0 million in 2018, then soared by 87.13% to $3.7 million in 2019, then spiked by 56.63% to $5.7 million in 2020, then spiked by 33.56% to $7.7 million in 2021, then climbed by 21.58% to $9.3 million in 2022.
  • Its Accumulated Depreciation & Amortization was $9.3 million in Q4 2022, compared to $7.7 million in Q4 2021 and $5.7 million in Q4 2020.